MONTREAL, June 5 /CNW Telbec/ - Akela Pharma Inc. (TSX: "AKL"), a drug
development company focused on developing therapies for the inhalation and
pain markets, today announced that it has been awarded a development and
manufacturing contract at its PharmaForm subsidiary located in Austin, Texas,
for development and manufacturing of a generic form of a commercial product
for an undisclosed pharmaceutical company. The contract is anticipated to
generate $1.5 - $2.0 M. in revenues over the next 12 - 18 months. The contract
includes technical transfer to support GMP manufacturing, process validation,
quality release testing and stability characterization. PharmaForm expects to
sign additional contracts with this client to support manufacture of clinical
supplies for an additional indication and commercial manufacturing in the near
future.
